TM6SF1

Across TCGA pan-cancer cohorts, TM6SF1 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TM6SF1 data layer compared with 23 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TM6SF1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TM6SF1 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

CCRCC, LSCC, and PDAC are the cancer types where TM6SF1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	1.000	0.508	.008	14	view →
LSCC	OS	Median	All	0.730	0.911	.011	13	view →
PDAC	DFS	Median	II,III,IV	0.437	0.680	.023	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

TM6SF1–CCRCC (DFS)

Open the CCRCC breakdown →